Revance Therapeutics reported $-62221000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Abbvie ABBV:US $ 4717M 357M
Aerie Pharmaceuticals AERI:US $ -33.64M 85.38M
ALKERMES ALKS:US -26585000 28.97M
Bristol Myers Squibb BMY:US $ 2553M 90M
Cara Therapeutics CARA:US $ -27911000 5.61M
Coherus Biosciences CHRS:US $ -87.15M 47.6M
Eli Lilly And LLY:US $ 2404.3M 487.1M
Endo International Ordinary Shares ENDP:US $ 68.99M 481.35M
Horizon Pharma HZNP:US $ 194.32M 38.77M
JAZZ PHA JAZZ:US $ 87.55M 38.17M
Johnson & Johnson JNJ:US $ 5862M 1026M
Merk MRK:US $ 5569M 1994M
Neurocrine Biosciences NBIX:US $ 3.1M 39.4M
Pacira Pharmaceuticals PCRX:US $ 17.39M 13.18M
Procter & Gamble PG:US $ 4024M 1144M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 1.97M 4.13M
Teva Pharmaceutical Industries TEVA:US $ -713M 791M